arbiter
JournalsPricingAccount

Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

Danmeng Huang et al.

Journal of Medical Economics2026https://doi.org/10.1080/13696998.2026.2639229article
ABDC C
Weight
0.50

What the paper says

After MAIC and subsequent immunotherapy adjustments, pembrolizumab plus chemotherapy showed improved overall survival and progression-free survival versus cemiplimab plus chemotherapy in both non-squamous and squamous metastatic NSCLC at modest incremental cost.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/13696998.2026.2639229

Or copy a formatted citation

@article{danmeng2026,
  title        = {{Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison}},
  author       = {Danmeng Huang et al.},
  journal      = {Journal of Medical Economics},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/13696998.2026.2639229},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Cost-effectiveness of pembrolizumab plus chemotherapy vs cemiplimab plus chemotherapy for first-line metastatic non–small cell lung cancer: a US payer perspective using a matching-adjusted indirect comparison

Flags are reviewed by the Arbiter methodology team within 5 business days.

Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.